Chugai Pharmaceutical (4519) Q3 2024 earnings summary

Executive summary

• Revenue and profits exceeded forecasts, driven by strong overseas sales, especially Hemlibra and Actemra exports, and one-time income, leading to an upward revision of full-year guidance.

• Operating profit and net income rose significantly year-over-year, with operating margin improving by 8.4 percentage points to 49.1%.

• Domestic sales declined due to the end of Ronapreve supply, NHI drug price revisions, and generic competition, but new and mainstay products showed growth.

• Development pipeline advanced with global approvals for PiaSky and NEMLUVIO, expanded indications for ALECENSA, and multiple product launches and filings across key therapeutic areas.

• R&D expenses increased 5.1% YoY, reflecting ongoing investments in early development and drug discovery.

Financial highlights

• Revenue for Jan–Sep 2024 was ¥868.5B (+3.7% YoY); operating profit ¥426.6B (+25.3% YoY); net income ¥301.3B (+20.4% YoY).

• Overseas sales grew 33.8% YoY to ¥418.7B; domestic sales fell 22.7% YoY to ¥331.7B.

• Cost to sales ratio improved to 32.5% from 43.1% YoY, reflecting a favorable product mix.

• EPS increased to ¥183.09 (+20.4% YoY); basic EPS: ¥179.75 (up from ¥142.40 YoY).

• Free cash flow for nine months: ¥238.2B; net cash at ¥845.3B (+14.4% vs. 2023 year-end).

Outlook and guidance

• Full-year revenue forecast raised to ¥1,150.0B (+7.5% vs. original), operating profit to ¥540.0B (+17.4%), and net income to ¥388.0B (+15.6%).

• Upward revisions reflect strong Hemlibra and Actemra exports, higher royalty and one-time income, and improved cost structure.

• Annual dividend forecast increased to ¥236.00 per share (+16.4% YoY), but year-end dividend remains undecided due to business environment changes.